Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

85Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

Abstract

Various statistical methods have been used to measure the impact of treatment on chronic obstructive pulmonary disease (COPD) exacerbations. Poisson regression has recently been recommended as the appropriate method but the model does not satisfactorily account for variability between patients. In contrast, use of a negative binomial model, which corresponds to assuming a separate Poisson parameter for each patient, offers a more appealing approach. The present paper reviews analysis methods, with particular focus on the negative binomial model. To illustrate the differences that arise from using different analysis methods, we have reanalysed data from two large studies which, among other objectives, investigated the effectiveness of inhaled corticosteroids in reducing COPD exacerbation rates. Using the negative binomial model to reanalyse data from the TRISTAN and ISOLDE studies, the overall estimates of exacerbation rates on each treatment arm are higher and the confidence intervals for comparisons between treatments are wider, but the overall conclusions of TRISTAN and ISOLDE regarding reduction of exacerbations remain unchanged. The negative binomial approach appears to provide a better fit to the distribution of the data than earlier methods and is currently the method of choice. Research needs to continue on further methods to improve the analysis of exacerbation data. Copyright©ERS Journals Ltd 2008.

References Powered by Scopus

Longitudinal data analysis using generalized linear models

14797Citations
N/AReaders
Get full text

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

4618Citations
N/AReaders
Get full text

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

2985Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mepolizumab treatment in patients with severe eosinophilic asthma

1897Citations
N/AReaders
Get full text

Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial

1892Citations
N/AReaders
Get full text

Mepolizumab and exacerbations of refractory eosinophilic asthma

1678Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Keene, O. N., Calverley, P. M. A., Jones, P. W., Vestbo, J., & Anderson, J. A. (2008, July). Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal. https://doi.org/10.1183/09031936.00161507

Readers over time

‘10‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

43%

Researcher 13

31%

Professor / Associate Prof. 9

21%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 36

77%

Engineering 4

9%

Mathematics 4

9%

Pharmacology, Toxicology and Pharmaceut... 3

6%

Save time finding and organizing research with Mendeley

Sign up for free
0